Junshi Biosciences, officially known as Junshi Pharmaceutical Co., Ltd., is a leading biopharmaceutical company headquartered in China. Founded in 2012, the company has rapidly established itself in the global biotechnology landscape, focusing on the research, development, and commercialisation of innovative therapies, particularly in oncology and autoimmune diseases. With a strong presence in major operational regions including Asia and North America, Junshi Biosciences is recognised for its cutting-edge monoclonal antibody products. Notably, its flagship product, toripalimab, has garnered significant attention for its unique mechanism of action in cancer treatment. The company has achieved remarkable milestones, including successful partnerships and regulatory approvals, positioning itself as a key player in the biopharmaceutical industry.
How does Junshi Biosciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Junshi Biosciences's score of 22 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Junshi Biosciences reported total carbon emissions of approximately 26,800,750 kg CO2e. This figure includes about 5,307,750 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and approximately 21,493,000 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. Currently, Junshi Biosciences has not established any specific reduction targets or climate pledges, nor do they have emissions data for Scope 3, which encompasses all other indirect emissions that occur in a company's value chain. The absence of reduction initiatives indicates a potential area for future commitment to climate action. The emissions data is sourced directly from Shanghai Junshi Biosciences Co., Ltd., with no cascading from a parent or related organization. As the company continues to grow, it may consider setting science-based targets to align with global climate goals and enhance its sustainability profile.
Access structured emissions data, company-specific emission factors, and source documents
2024 | |
---|---|
Scope 1 | 5,307,750 |
Scope 2 | 21,493,000 |
Scope 3 | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Junshi Biosciences is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.